Compare GERN & ELVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | ELVR |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | Australia |
| Employees | 258 | 230 |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 941.8M |
| IPO Year | N/A | N/A |
| Metric | GERN | ELVR |
|---|---|---|
| Price | $1.26 | $91.69 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | ★ 13.9M | 70.1K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | $90.73 |
| Revenue Next Year | $43.75 | $42.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $15.55 |
| 52 Week High | $2.01 | $101.50 |
| Indicator | GERN | ELVR |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 57.12 |
| Support Level | $1.22 | $77.29 |
| Resistance Level | $1.29 | $101.50 |
| Average True Range (ATR) | 0.06 | 3.53 |
| MACD | -0.00 | -0.79 |
| Stochastic Oscillator | 21.15 | 61.09 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.